Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Cash Flow Conversion Efficiency

Latest as of June 2023: 0.059x

Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has a cash flow conversion efficiency ratio of 0.059x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.10 Billion ≈ $2.45 Billion USD) by net assets (€35.38 Billion ≈ $41.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GU5 net asset quality score to measure how much of total assets are equity-financed.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Guangzhou Baiyunshan Pharmaceutical Hold to evaluate the quality of earnings relative to operating cash generation.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shinhan Alpha REIT Co Ltd KO:293940	0.005x
Beijing Hezong Science&Technology Co Ltd SHE:300477	0.068x
Fujian Minfa Aluminium Co Ltd SHE:002578	-0.035x
Kaveri Seed Company Limited NSE:KSCL	-0.083x
Hubei Xiangyuan New Material Technology Inc. SHE:300980	0.004x
Israel Land Development Company Co Ltd TA:ILDC	0.013x
Lion Travel Service Co Ltd TW:2731	0.143x
Foseco India Limited NSE:FOSECOIND	0.045x

Annual Cash Flow Conversion Efficiency for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see GU5 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€40.08 Billion ≈ $46.86 Billion	€-232.46 Million ≈ $-271.77 Million	-0.006x	-106.36%
2024-12-31	€37.77 Billion ≈ $44.16 Billion	€3.44 Billion ≈ $4.02 Billion	0.091x	-18.54%
2023-12-31	€36.68 Billion ≈ $42.88 Billion	€4.10 Billion ≈ $4.80 Billion	0.112x	-46.23%
2022-12-31	€33.64 Billion ≈ $39.33 Billion	€7.00 Billion ≈ $8.18 Billion	0.208x	+14.89%
2021-12-31	€31.33 Billion ≈ $36.62 Billion	€5.67 Billion ≈ $6.63 Billion	0.181x	+772.92%
2020-12-31	€28.21 Billion ≈ $32.97 Billion	€585.19 Million ≈ $684.14 Million	0.021x	-89.26%
2019-12-31	€25.99 Billion ≈ $30.38 Billion	€5.02 Billion ≈ $5.87 Billion	0.193x	-14.27%
2018-12-31	€23.14 Billion ≈ $27.06 Billion	€5.22 Billion ≈ $6.10 Billion	0.225x	+136.80%
2017-12-31	€19.26 Billion ≈ $22.52 Billion	€1.83 Billion ≈ $2.14 Billion	0.095x	-33.96%
2016-12-31	€17.65 Billion ≈ $20.64 Billion	€2.54 Billion ≈ $2.97 Billion	0.144x	-35.54%
2015-12-31	€8.68 Billion ≈ $10.15 Billion	€1.94 Billion ≈ $2.27 Billion	0.224x	+1.31%
2014-12-31	€7.92 Billion ≈ $9.26 Billion	€1.75 Billion ≈ $2.04 Billion	0.221x	+15.99%
2013-12-31	€7.02 Billion ≈ $8.21 Billion	€1.34 Billion ≈ $1.56 Billion	0.190x	--

About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

F:GU5 Germany Medical Distribution

Market Cap

$429.33 Million

€367.23 Million EUR

Market Cap Rank

#12963 Global

#1373 in Germany

Share Price

€1.67

Change (1 day)

-1.18%

52-Week Range

€1.55 - €2.30

All Time High

€2.30